Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma

Cancer Gene Therapy

Volumn 18, Issue 8, 2011, Pages 571-578

  Kawasaki, Y ^a   Tamamoto, A ^a   Takagi Kimura, M ^a   Maeyama, Y ^a   Yamaoka, N ^a   Terada, N ^a   Okamura, H ^a   Kasahara, N ^b   Kubo, S ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

malignant mesothelioma; molecular imaging; prodrug activator gene therapy; replication competent retrovirus vector

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; GREEN FLUORESCENT PROTEIN; REPLICATION COMPETENT RETROVIRUS VECTOR; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL VIABILITY; CYTOTOXICITY; DRUG EFFICACY; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADULT; ANIMALS; CELL LINE, TUMOR; CYTOSINE DEAMINASE; DISEASE MODELS, ANIMAL; FEMALE; FLUCYTOSINE; GENE THERAPY; HUMANS; MALE; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PRODRUGS; RETROVIRIDAE; SURVIVAL ANALYSIS; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

MUS;

EID: 79960556047     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.25     Document Type: Article

References (28)

1. Ismail-Khan R, Robinson LA, Williams Jr CC, Garrett CR, Bepler G, Simon GR. Malignant pleural mesothelioma: a comprehensive review. Cancer Control 2006; 13: 255-263. (Pubitemid 44600936)
2. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009; 27: 2081-2090.
3. van der Most RG, Robinson BW, Nelson DJ. Gene therapy for malignant mesothelioma: beyond the infant years. Cancer Gene Ther 2006; 13: 897-904. (Pubitemid 44373790)
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644. (Pubitemid 46606305)
5. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397-408. (Pubitemid 41073959)
6. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727. (Pubitemid 30460686)
7. Liu TC, Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther 2008; 15: 877-884. (Pubitemid 351791475)
8. Fukazawa T, Matsuoka J, Naomoto Y, Maeda Y, Durbin ML, Tanaka N. Malignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapy. Cancer Res 2008; 68: 7120-7129.
9. Zhu ZB, Makhija SK, Lu B, Wang M, Wang S, Takayama K et al. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses. J Thorac Oncol 2006; 1: 701-711. (Pubitemid 47163960)
10. Brader P, Kelly KJ, Chen N, Yu YA, Zhang Q, Zanzonico P et al. Imaging a genetically engineered oncolytic vaccinia virus (GLV-1h99) using a human norepinephrine transporter reporter gene. Clin Cancer Res 2009; 15: 3791-3801.
11. Adusumilli PS, Stiles BM, Chan MK, Mullerad M, Eisenberg DP, Ben-Porat L et al. Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. J Gene Med 2006; 8: 603-615. (Pubitemid 43827253)
12. Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J et al. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res 2009; 69: 7713-7720.
13. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239-4242.
14. Hiraoka K, Kimura T, Logg CR, Tai CK, Haga K, Lawson GW et al. Therapeutic efficacy of replicationcompetent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res 2007; 67: 5345-5353. (Pubitemid 46997274)
15. Kikuchi E, Menendez S, Ozu C, Ohori M, Cordon-Cardo C, Logg CR et al. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors. Clin Cancer Res 2007; 13: 4511-4518. (Pubitemid 47219721)
16. Tai CK, Wang WJ, Chen TC, Kasahara N. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther 2005; 12: 842-851. (Pubitemid 41614479)
17. Wang WJ, Tai CK, Kasahara N, Chen TC. Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther 2003; 14: 117-127. (Pubitemid 36418816)
18. Logg CR, Tai CK, Logg A, Anderson WF, Kasahara N. A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum Gene Ther 2001; 12: 921-932. (Pubitemid 32681856)
19. Kubo S, Seleme MC, Soifer HS, Perez JL, Moran JV, Kazazian Jr HH et al. L1 retrotransposition in nondividing and primary human somatic cells. Proc Natl Acad Sci USA 2006; 103: 8036-8041. (Pubitemid 43801048)
20. Kubo S, Mitani K. A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector. J Virol 2003; 77: 2964-2971. (Pubitemid 36228081)
21. Kubo S, Kawasaki Y, Yamaoka N, Tagawa M, Kasahara N, Terada N et al. Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus. J Gene Med 2010; 12: 681-692.
22. Yamaoka N, Kawasaki Y, Xu Y, Yamamoto H, Terada N, Okamura H et al. Establishment of in vivo fluorescence imaging in mouse models of malignant mesothelioma. Int J Oncol 2010; 37: 273-279.
23. Albelda SM, Wiewrodt R, Sterman DH. Gene therapy for lung neoplasms. Clin Chest Med 2002; 23: 265-277. (Pubitemid 34205620)
24. Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005; 11: 7444-7453. (Pubitemid 41507705)
25. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9: 1083-1092. (Pubitemid 28236516)
26. Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007; 13: 4456-4466. (Pubitemid 47219714)
27. Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010; 18: 852-860.
28. Hiraoka K, Kimura T, Logg CR, Kasahara N. Tumor-selective gene expression in a hepatic metastasis model after locoregional delivery of a replication-competent retrovirus vector. Clin Cancer Res 2006; 12: 7108-7116. (Pubitemid 44974511)